Testing the sensitivity and specificity of EUROLINE immunoblots for systemic sclerosis and autoimmune muscle diseases

Testing the sensitivity and specificity of EUROLINE immunoblots for systemic sclerosis and autoimmune muscle diseases - Sensitivity and specificity testing Immunoblots

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00030945

Enrollment

2000

Registered

2023-03-01

Start date

2023-03-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M34.0 M34.1 M34.8 M34.9 L94.0 M33.0 M33.1 M33.2 M33.9 M60.9

Interventions

Group 1: Outpatients and inpatients with a positive as well as negative EUROLINE immunoblot test result for systemic sclerosis or autoimmune muscle disease

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Outpatient and inpatient treatment at UKH in the period from 01.01.2018 to 31.12.2021. - Existing test result in the immunoblot EUROLINE for a systemic sclerosis or autoimmune muscle disease. - Confirmed diagnosis by the clinical phenotype of one of the above-mentioned forms of progression, documented in the medical report or in the medical outpatient documentation.

Exclusion criteria

Exclusion criteria: - Positive blot results without documented diagnosis in the physician's report or in the physician's outpatient documentation

Design outcomes

Primary

Measure	Time frame
Sensitivity and specificity of the immunoblot EUROLINE	—

Secondary

Measure	Time frame
Likelihood Ratio for the Immunoblot EUROLINE	—

Countries

Germany

Contacts

Public ContactNancy Garbe

Universitätsklinikum Halle Saale, Klinik für Innere Medizin II, Rheumatologie

nancy.garbe@uk-halle.de493455571996

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026